Myasthenia gravis: open trials in Canada

8 open trials have a site in Canada. Registry data; only the trial team decides who can take part.

NCT07463521
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
Trial Treatment · Phase 3 · UCB Biopharma SRL
Mg0038 10201, Montreal
Registry updated 2026-11-06
NCT04951622
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
Trial Treatment · Phase 3 · Janssen Research & Development, LLC
McGill University, Montreal · The Ottawa Hospital Research Institute, Ottawa · Toronto General Hospital, Toronto
Registry updated 2026-11-05
NCT05374590
Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis
Trial Treatment · Phase 2/3 · argenx
Alberta Childrens Hospital, Calgary · Childrens Hospital of Eastern Ontario, Ottawa
Registry updated 2026-11-03
NCT06765161
Efgartigimod in IVIG Dependent Myasthenia Gravis Patients
Trial Treatment · Phase 3 · Clinique Neuro-Outaouais
Clinique Neuro-Outaouais, Gatineau
Registry updated 2026-10-22
NCT06463587
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
Trial Treatment · Phase 3 · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Burnaby Hospital - Fraser Health Multiple Sclerosis Clinic, Burnaby
Registry updated 2026-10-21
NCT07304154
Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment
Trial Treatment · Phase 1 · Kite, A Gilead Company
Centre Intégré Universitaire de Sante et Services Sociaux de L'Est de I'lle de Montreal / installation Hopital Maisonneuve-Rosemont, Montreal · Jewish General Hospital, Montreal · The Ottawa Hospital - General Campus, Ottawa
Registry updated 2026-10-19
NCT06392386
A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis
Trial Treatment · Phase 2/3 · argenx
Childrens Hospital of Eastern Ontario, Ottawa
Registry updated 2026-09-28
NCT04202341
Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
Research · Alexion Pharmaceuticals, Inc.
Brampton · London · Montreal
Registry updated 2026-02-18

All Myasthenia gravis trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error